Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125388162 | 12538816 | 2 | F | 20160808 | 20160708 | 20160810 | PER | PHEH2016US016531 | NOVARTIS | 0.00 | M | Y | 0.00000 | 20160810 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125388162 | 12538816 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 9.5 MG, QD (PATCH 10 CM2) | U | 4345C | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||
| 125388162 | 12538816 | 2 | C | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | Unknown | UNK | U | 0 | |||||||||
| 125388162 | 12538816 | 3 | C | SINGULAIR | MONTELUKAST SODIUM | 1 | Unknown | UNK | U | 0 | |||||||||
| 125388162 | 12538816 | 4 | C | RHINOCORT | BUDESONIDE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125388162 | 12538816 | 1 | Product used for unknown indication |
| 125388162 | 12538816 | 2 | Product used for unknown indication |
| 125388162 | 12538816 | 3 | Product used for unknown indication |
| 125388162 | 12538816 | 4 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125388162 | 12538816 | Product adhesion issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |